Skip to main content
. 2011 Jul 8;68(1):29–37. doi: 10.1007/s00228-011-1094-4

Fig. 4.

Fig. 4

Changes in systemic clearance of aripiprazole (APZ) by coadministration of clinical doses of paroxetine (PRX) and of fluvoxamine (FLV) in CYP2D6 EMs and IMs for each subject. Extensive metabolizers (EM) and intermediate metabolizers (IM) are shown, respectively, with solid lines and dashed lines